Bluebird Spins Off Oncology Business As Cell, Gene Therapy Segments Grow Apart
Gene Therapy Focus Opens Partnering, Acquisition Opportunities
Nick Leschly will become CEO of oncology-focused spinoff, while Andrew Obenshain will help gene therapy-focused bluebird
